[{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Aztreonam","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Nordic Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Nordic Capital","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Nordic Capital"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Advanz Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Divestment","leadProduct":"Obeticholic Acid","moa":"Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"||Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Advanz Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Applied Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Suspension","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Correvio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Vernakalant Hydrochloride","moa":"Kir3.1\/Kir3.4 | Voltage-gated potassium channel subunit Kv4.3 | Voltage-gated potassium channel subunit Kv1.5 | Sodium channel protein type V alpha subunit | HERG","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"PolyPid","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Powder, Extended Release","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Alprostadil","moa":"Prostanoid EP1 receptor | Prostanoid EP2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Alprostadil","moa":"Prostanoid EP1 receptor | Prostanoid EP2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody-drug Conjugate","year":"2025","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.34000000000000002,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ICELAND","productType":"Protein","year":"2024","type":"Agreement","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ICELAND","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Advanz Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Mynzepli (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.

                          Product Name : Mynzepli

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 21, 2025

                          Lead Product(s) : Aflibercept

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Recipient : Alvotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : The agreement aims for the supply and commercialization of AVT10, Alvotech’s biosimilar candidate to Cimzia (certolizumab pegol).

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          July 01, 2025

                          Lead Product(s) : Certolizumab Pegol

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Recipient : Alvotech

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Advanz secures exclusive rights from Alvotech to commercialize three biosimilar candidates, Ilaris (canakinumab), Kesimpta (ofatumumab) and an undiclosed biosimilar in Europe.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          May 28, 2025

                          Lead Product(s) : Canakinumab

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Recipient : Alvotech

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist, which is indicated for the treatment of individuals with primary biliary cholangitis.

                          Product Name : Ocaliva

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 02, 2024

                          Lead Product(s) : Obeticholic Acid

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Under the agreement, Alvotech will develop AVT06 (Aflibercept) biosimilar to Eylea. Advanz Pharma will be responsible for registration and commercializing in Europe, except for Germany and France.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          June 19, 2024

                          Lead Product(s) : Aflibercept

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Recipient : Alvotech

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : UK MHRA approved Exblifep (cefepime/enmetazobactam) antibiotic which is indicated to treat adults suffering from complicated UTIs and certain kinds of pneumonia acquired during hospital stays.

                          Product Name : Exblifep

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          April 05, 2024

                          Lead Product(s) : Cefepime,Enmetazobactam

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Advanz Pharma secures exclusive rights from Alvotech to commercialize AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab), AVT16, a proposed biosimilar to Entyvio (vedolizumab), and three additional early-stage, undisclosed biosimilar c...

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : $60.1 million

                          May 24, 2023

                          Lead Product(s) : Golimumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Recipient : Alvotech

                          Deal Size : $343.4 million

                          Deal Type : Partnership

                          blank

                          08

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Palmeux (paliperidone palmitate) is a second-generation antipsychotic, also known as an atypical antipsychotic (simultaneous serotonin and dopamine antagonist) for the treatment of schizophrenia in adult patients.

                          Product Name : Palmeux

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 17, 2023

                          Lead Product(s) : Paliperidone Palmitate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Under the terms of the agreement, Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand and Alvotech will be responsible for development a...

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          February 06, 2023

                          Lead Product(s) : Omalizumab

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Recipient : Alvotech

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : AT-007 (gavorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : $10.6 million

                          January 04, 2023

                          Lead Product(s) : Govorestat

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Recipient : Applied Therapeutics

                          Deal Size : $138.4 million

                          Deal Type : Partnership

                          blank